1. Anderson J, Fawdry R, Gordon E, Coyle S, Gruenewald S, Meares RA. SPECT asymmetry of left temporal lobe in hallucinated schizophrenics. Biol Psychiatry 1991;29:291.

2. Andreasen NC, Carson R, Diksic M, et al. PET and dopamine D2 receptors in the human neostriatum. Schizophr Bull 1988;14:471-484.

3. Andreasen NC, Rezai K, Alliger R, et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: Assessment with Xenon 133 single-photon emission computed tomography and the tower of London. Arch Gen Psychiatry 1992;49:943-958.

4. Bartlett EJ, Barouche F, Brodie JD, et al. Stability of resting deoxyglucose metabolic values in PET studies of schizophrenia. Psychiatry Res 1991;40:11-20.

5. Bartlett EJ, Woklin A, Brodie JD, Laska EM, Wolf AP, Sanfilipo M. Importance of pharmacologic control in PET studies: Effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia. Psychiatry Res 1991;40:115-124.

6. Berman KF, Ostrem JL, Randolph C, et al. Physiological activation of a cortical network during performance of the Wisconsin card sorting test: A positron emission tomography study. Neuropsychologia 1995;33:1027-1046.

7. Berman KF, Weinberger DR. Lateralization of cortical function during cognitive tasks: regional cerebral blood flow studies of normal individuals and patients with schizophrenia. J Neurol Neurosurg Psychiatry 1990;53:150-160.

8. Biver F, Goldman S, Luxen A, et al. Altered frontostriatal relationship in unmedicated schizophrenic patients. Psychiatry Res 1995;61:161-171.

9. Bogerts B, Falkai P, Greve B. Evidence of reduced temporolimbic structure volumes in schizophrenia letter. Arch Gen Psychiatry 1991;48:956-958.

10. Brucke T, Tsai YF, McLellan CA, et al. In vitro binding properties and autoradiographic imaging of 3-iodobenzamide ([125I]-IBZM): a potential imaging ligand for D2 dopamine receptors in SPECT. Life Sci 1988;42:2097-2104.

11. Buchsbaum MS, Ingvar DH, Kessler R, et al. Cerebral glucography with positron tomography. Arch Gen Psychiatry 1987;39:251-259.

12. Buchsbaum MS, Potkin SG, Marshall JF, et al. Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. Neuropsychopharmacology 1992;6:155-163.

13. Buchsbaum MS, Potkin SG, Siegel BV, Jr, et al. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatry 1992;49:966-974.

14. Buchsbaum MS, Someya T, Teng CY, et al. PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiatry 1996;153:191-199.

15. Buchsbaum MS. The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia. Schizophr Bull 1990;16:377-387.

16. Chumpradit S, Kung M-P, Billings J, Mach R, Kung HF. Fluorinated and iodinated dopamine agents (FIDA): D2 imaging agents for PET and SPECT. J Med Chem 1993;36:221-228.

17. Cleghorn J.M, Garnett ES, Nahmias C, et al. Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. Psychiatry Res 1989;28:119-133.

18. Cleghorn JM. Regional brain metabolism during auditory hallucinations in chronic schizophrenia. Br J Psychiatry 1990;157:562-570.

19. Crow TJ. Temporal lobe asymmetries as the key to the etiology of schizophrenia. Schizophr Bull 1990;16:433-443.

20. Davis KL, Kah RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148:1474-1486.

21. DeLisi LE, Buchsbaum MS, Holcomb HH, et al. Increased temporal lobe glucose use in chronic schizophrenic patients. Biol Psychiatry 1989;25(7):835-851.

22. DeLisi LE, Holcomb HH, Cohen RM, et al. Positron emission tomography in schizophrenic patients with and without neuroleptic medication. J Cereb Blood Flow Metab 1985;5:201-206.

23. Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 1995;378:180-182.

24. Early TS, Reiman EM, Raichle, ME, Spitznagel EL. Left globus pallidus abnormality in never-mediated patients with schizophrenia. Proc Natl Acad Sci USA 1989;84:561-563.

25. Farde L, Nordstrom AL. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 1992;160:30-33.

26. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. PET analysis of central D1 and D2 dopamine receptor occupancy in patients treated with chemical neuroleptics and clozapine: Relation to extra-pyramidal side effects. Arch Gen Psychiatry 1992;49:538-544.

27. Farde L, Wiesel FA, Stone-Elander S, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients: a positron emission tomography study with 11C raclopride. Arch Gen Psychiatry 1990;47:213-219.

28. Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45:71-76.

29. Farde L. Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans—a PET study with [11C]SCH 23390 and [11C]raclopride. Psychopharmacology 1992;107:23-29.

30. Frith CD, Friston KJ, Herold S, et al. Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. Br J Psychiatry 1995;167:343-349.

31. Gur RC, Erwin RJ, Gur RE. Neurobehavioral probes for physiologic neuroimaging studies. Arch Gen Psychiatry 1992;49:409-414.

32. Gur RC, Gur RE, Skolnick BE, et al. Effects of task difficulty on regional cerebral blood flow: relationships with anxiety and performance. Psychophysiology 1988;25:392-399.

33. Gur RC, Gur RE, Obrist WD, et al. Sex and handedness differences in cerebral blood flow during rest and cognitive activity. Science 1982;217:659-661.

34. Gur RC, Jaggi JL Ragland, et al. Effects of memory processing on regional brain activation: Cerebral blood flow in normal subjects. Int J Neurosci 1993;72:31-44.

35. Gur RE, Gur RC, Skolnick BE, et al. Brain function in psychiatric disorders: III. Regional cerebral blood flow in unmedicated schizophrenics. Arch Gen Psychiatry 1985;42:329-334.

36. Gur RE, Gur RC. Neurotransmitters are important, but so is metabolism. Neuropsychopharmacology 1992;7:63-65.

37. Gur RE, Mozley PD, Resnick SM, et al. Resting cerebral glucose metabolism and clinical features of schizophrenia. Arch Gen Psychiatry 1995;52:657-667.

38. Gur RE, Pearlson GD. Neuroimaging in schizophrenia research. Schizophr Bull 1993;19:337-353.

39. Gur RE, Resnick SM, Alavi A, et al. Regional brain function in schizophrenia. I. A positron emission tomography study. Arch Gen Psychiatry 1987;44:119-25.

40. Gur RE, Resnick SM, Gur RC. Laterality and frontality of cerebral blood flow and metabolism in schizophrenia: relationship to symptom specificity. Psychiatry Res 1989;27:325-34.

41. Gur RE, Resnick SM, Gur RC, et al. Regional brain function in schizophrenia. II. Repeated evaluation with positron emission tomography. Arch Gen Psychiatry 1987;44:126-129.

42. Gur RE, Skolnick BE, Gur RC, et al. Brain function in psychiatric disorders: I. Regional cerebral blood flow in medicated schizophrenics. Arch Gen Psychiatry 1983;40:1250-1254.

43. Gur RE. Left hemisphere dysfunction and left hemisphere overactivation in schizophrenia. J Abnorm Psychol 1978;87:226-238.

44. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 1996;153:41-49.

45. Ingvar DH, Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand 1974;50:425-462.

46. Kapur S, Remington G, Jones C, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: A PET study. Am J Psychiatry 1996;153:948-950.

47. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A PET study. Life Sci 1995;57:103-107.

48. Kawasaki Y, Maeda Y, Suzuki M, et al. SPECT analysis of rCBF changes during Wisconsin Card Sorting Test. Biol Psychiatry 1991;29:333S-701S.

49. Kawasaki Y, Maeda Y Suzuki M, et al. SPECT analysis of regional cerebral blood flow changes in patients with schizophrenia during the Wisconsin Card Sorting Test. Schizophr Res 1993;10:109-116.

50. Kessler RM, Ansari MS, Schmidt DE, et al. High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. Life Sci 1991;49:617-628.

51. Kling AS, Metter EJ, Riege WH, Kuhl DE. Comparison of PET measurement of local brain glucose metabolism and CAT measurement of brain atrophy in chronic schizophrenia and depression. Am J Psychiatry 1986;143:175-180.

52. Konig P, Benzer MK, Fritzsche H. SPECT technique for visualization of cerebral dopamine D2 receptors. Am J Psychiatry 1991;148:1607-1608.

53. Kotrla KJ, Weinberger DR. Brain imaging in schizophrenia. Ann Rev Med 1995;46:113-122.

54. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RSJ. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992;160:179-186.

55. Lieberman JA, Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia: A selective review. Schizophr Bull 1993;19:371-429.

56. Martinot JL, Paillere-Martinot ML, Loc'h C, et al. The estimated density of D2 striatal receptors in schizophrenia: a study with positron emission tomography and 76Br-bromolisuride. Br J Psychiatry 1991;158:346-350.

57. Martinot JL, Peron-Magnan P, Huret JD, et al. Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients. Am J Psychiatry 1990;147:44-50.

58. Mathew RJ, Wilson WH, Tant SR, Robinson L, Prakash R. Abnormal resting regional cerebral blood flow patterns and their correlates in schizophrenia. Arch Gen Psychiatry 1988;45:542-549.

59. McGuire PK, Silbersweig DA, Wright I, et al. Abnormal monitoring of inner speech: a physiological basis for auditory hallucinations. Lancet 1995;346:596-600.

60. Mozley LH, Gur RC, Gur RE, Mozley PD, Alavi A. The relationship between verbal memory performance and the cerebral distribution of FDG in patients with schizophrenia. Biol Psychiatry 1996;40:443-451.

61. Mozley PD, Stubbs JB, Kung HF, Selikson MH, Stabin MG, Alavi A. Biodistribution and dosimetry of I-123 IBF: A potent SPECT radioligand for imaging the D2 dopamine receptor. J Nucl Med 1993;34:1910-1917.

62. Mozley PD, Zhu X, Kung HF, et al. The dosimetry of I-123 labeled TISCH: A SPECT imaging agent for the D1 dopamine receptor. J Nucl Med 1993;34:208-213.

63. Musalek M, Podreka I, Walter H, et al. Regional brain function in hallucinations: A study of regional cerebral blood flow with 99m-Tc-HMPAO-SPECT in patients with auditory hallucinations, tactile hallucinations, and normal controls. Compr Psychiatry 1989;30:99-108.

64. Nordstrom AL, Farde L, Eriksson L, Halldin C. No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. Psychiatry Res 1995;61:67-83.

65. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-235.

66. O'Leary DS, Andreasen NC, Hurtig RR, et al. Auditory attentional deficits in patients with schizophrenia. A positron emission tomography study. Arch Gen Psychiatry 1996;53:633-641.

67. Pearlson GD, Tune LE, Wong DF, et al. Quantitative D2 dopamine receptor PET and structural MRI changes in late-onset schizophrenia. Schizophr Bull 1993;19:783-795.

68. Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murray RM, Kerwin RW. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry 1994;164:16-26.

69. Renshaw PF, Yurgelun-Todd DA, Cohen BM. Greater hemodynamic response to photic stimulation in schizophrenic patients: An echo planar MRI study. Am J Psychiatry 1994;151:1493-1495.

70. Rubin P, Holm S, Friberg L, et al. Altered modulation of prefrontal and subcortical brain activity in newly diagnosed schizophrenia and schizophreniform disorder: a regional cerebral blood flow study. Arch Gen Psychiatry 1991;48:987-995.

71. Rubin P, Holm S, Friberg L, et al. rCBF (SPECT) and CT measurements during first episode schizophrenia and schizophreniform psychosis. Biol Psychiatry 1991;29:270.

72. Rubin P, Holm S, Madsen PL, et al. Regional cerebral blood flow distribution in newly diagnosed schizophrenia and schizophreniform disorder. Psychiatry Res 1994;53:57-75.

73. Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry 1991;48:618-624.

74. Schlyer DJ, Voklow ND, Fowler JD, et al. Regional distribution and kinetics of haloperidol binding in human brain: A PET study with [18F]haloperidol. Synapse 1992;11:10-19.

75. Sedvall G, Farde L, Persson A, Weisel FA. Imaging of neurotransmitter receptors in the living human brain. Arch Gen Psychiatry 1986;3:995-1005.

76. Sedvall GC. The current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology 1992;7:41-54.

77. Sheppard G, Gruzelier J, Manchanda R, et al. 15-O positron emission tomographic scanning in predominantly never-treated acute schizophrenic patients. Lancet 1983;2:1448-1452.

78. Siegel BV, Buchsbaum MS, Bunney WE, Jr, et al. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am J Psychiatry 1993;150:1325-1336.

79. Tamminga CA, Thaker GK, Buchanan R, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992;49:522-530.

80. Vita A, Bressi S, Perani D, et al. High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients. Am J Psychiatry 1995;152:876-882.

81. Vita A, Giobbo GM, Dieci M, Garbarini M, Castignoli G, Invernizzi G. Frontal lobe dysfunction in schizophrenia: Evident from neuropsychological testing and brain imaging techniques. Biol Psychiatry 1991;29:647-S.

82. Volkow ND, Wolf AP, Van Gelder, et al. Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia. Am J Psychiatry 1987;144:151-158.

83. Volkow ND, Wolf AP, Brodie JD, et al. Brain interactions in chronic schizophrenics under resting and activation conditions. Schizophr Res 1988;1:47-53.

84. Wagner HN, Burns HD, Dannals RF, et al. Imaging dopamine receptors in the human brain by positron emission tomography. Science 1983;221:1264-1266.

85. Warach S, Gur RC, Gur RE, Skolnick BE, Obrist WD, Reivich M. The reproducibility of the Xe-133 inhalation technique in resting studies: task order and sex related effects in healthy young adults. J Cereb Blood Flow and Metab 1987;7:702-708.

86. Weinberger DR, Berman KF, Illowsky B. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 1988;45:609-615.

87. Weinberger DR, Berman KF, Suddath R, Torrey EF. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: A magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 1992;149:890-897.

88. Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 1986;43:114-125.

89. Wenz F, Schad LR, Knopp MV, et al. Functional magnetic resonance imaging at 1.5 T: Activation pattern in schizophrenic patients receiving neuroleptic medication. Mag Res Imaging 1994;12:975-982.

90. Wiesel FA, Wiik G, Sjogren I, Blomqvist G, Greitz T, Stone-Elander S. Regional brain glucose metabolism in drug free schizophrenic patients and clinical correlates. Acta Psychiatr Scand 1987;76:628-641.

91. Wolkin A, Angrist B, Wolf A, et al. Low frontal glucose utilization in chronic schizophrenia: a replication study. Am J Psychiatry 1988;145:251-253.

92. Wolkin A, Barouche F, Wolf AP, et al. Dopamine blockade and clinical response: Evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989;146:905-908.

93. Wolkin A, Jaeger J, Brodie JD, et al. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry 1985;142:564-571.

94. Wong DF, Wagner HN, Pearlson G, et al. Dopamine receptor binding of C-11-3-N-methylspiperone in the caudate in schizophrenia and bipolar disorder: a preliminary report. Psychopharmacol Bull 1985;21:595-598.

95. Wong DF, Wagner HN, Tune LE, et al. Positron emission tomography reveals elevated D2 receptors in drug-naive schizophrenics. Science 1986;239:1473-1624.

96. Wood F, Flowers DL. Hypofrontal vs. Hypo-Sylvian blood flow in schizophrenia. Schizophr Bull 1990;16:413-424.

97. Yurgelun-Todd DA, Waternaux CM, Cohen BM, Gurber SA, English CD Renshaw PF. Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production. Am J Psychiatry 1996;153:200-205.

Back to Chapter